Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Journal of Ophthalmic Inflammation and Infection

Camilo Brandão-de-Resende¹  Carlos Pavesio²  Ilaria Testi²  Rupesh Agrawal³ 

[1] Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust, London, UK;Department of Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, UK;Department of Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, UK;National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore;Singapore Eye Research Institute, Singapore, Singapore;Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore;The Ophthalmology & Visual Sciences Academic Clinical Programme, Duke NUS Medical School, Singapore, Singapore;

关键词: Uveitis;    Ocular inflammation;    Immunomodulatory;    Coronavirus disease;    COVID-19;    SARS-CoV-2;    Vaccination;   

DOI  :  10.1186/s12348-021-00275-x

来源: Springer

【 摘 要 】

BackgroundInflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions.MethodsMultinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021.ResultsSeventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%).ConclusionOcular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.

【 授权许可】

CC BY